Intraoperative ultrasound can decrease the re-excision lumpectomy rate in patients with palpable breast cancers

Karole M. Davis, Chiu Hsieh Hsu, Marcia E. Bouton, Krista L. Wilhelmson, Ian K. Komenaka

Research output: Contribution to journalArticlepeer-review

33 Scopus citations

Abstract

Positive margins occur in 15 to 69 per cent of patients undergoing lumpectomy. The current study was performed to evaluate intraoperative ultrasound in patients undergoing lumpectomy for palpable breast cancer. A retrospective chart review was performed of patients with palpable cancer who underwent lumpectomy with intraoperative ultrasound from 2004 to 2009. Each patient was matched with two patients who underwent lumpectomy alone over the same time period.Matching criteria included tumor size, clinical stage, body mass index, age at diagnosis, and lymphovascular invasion or extensive intraductal component. Twenty-two consecutive patients who underwent lumpectomy with intraoperative ultrasound were matched with 44 patients who underwent lumpectomy without intraoperative ultrasound. In addition to matching criteria, the patients were similar with respect to ethnicity, insurance status, weight, predominant histology, estrogen receptor, progesterone receptor, and Her2 status. Patients who underwent lumpectomy with intraoperative ultrasound were significantly less likely to have an involved margin (41 vs 9%, P = 0.01) and less likely to require a re-excision (34 vs 9%, P = 0.04). The lumpectomy volumes in the intraoperative ultrasound group were smaller than the volumes in the lumpectomy alone group. Intraoperative ultrasound can decrease the rate of positive margins and re-excision lumpectomy in patients with palpable breast cancers.

Original languageEnglish (US)
Pages (from-to)720-725
Number of pages6
JournalAmerican Surgeon
Volume77
Issue number6
StatePublished - Jun 2011

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Intraoperative ultrasound can decrease the re-excision lumpectomy rate in patients with palpable breast cancers'. Together they form a unique fingerprint.

Cite this